Qrons Inc.
QRON
Other OTC0.01
USD
+0.00
- -
CIK
0001689084
ISIN
US74737F1012
CUSIP
74737F101
Return %
Stock
S&P500
1Y
-77.80
19.01
3Y
-97.29
65.48
5Y
-97.64
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Cory J. Rosenberg
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Koblenzer Strasse 2 Glendale BY United States of America 86368
- IPO Date
- Jul 14, 2021
- CIK
- 0001689084
- Website
- quantron.net
- Similar Companies
- Business
- Qrons Inc. (QRON) is a biotechnology company that develops products, treatments, and technologies to combat neuronal and infectious diseases, with a focus on traumatic brain injuries, neurodegenerative conditions, antibiotic-resistant bacteria, and sepsis; its core product candidates include QS100, an injury-specific, 3D-printable, implantable mesenchymal stem cells-synthetic hydrogel for penetrating brain injuries, and QS200, an injectable mesenchymal stem cells-synthetic hydrogel for concussions and diffused axonal injuries; the company also leverages proprietary synthetic hydrogels, Tellurium-based compounds, and patented technologies such as Techniques for Promoting Neuronal Recovery, Therapeutic Polypseudorotaxane Hydrogels, and Tellurium Compositions and Techniques for Use Therewith. Founded in 2016 and formerly known as BioLabMart Inc. until its name change in August 2017, Qrons Inc. is headquartered in Long Island City, New York, with research centered in Israel and operations extending to the United States and collaborations involving institutions like Dartmouth College and universities in Israel. In January 2025, Qrons Inc. completed its acquisition by First Person Ltd. through a reverse merger transaction, following a letter of intent signed in October 2024 and a merger agreement that involved issuing Series B Convertible Preferred Stock to First Person shareholders, subject to funding commitments, anti-dilution agreements, and customary closing conditions. Recent advancements include a 2023 collaboration with an Israeli public research university to explore Tellurium-based compounds with QS200 for diffused axonal injuries and antibiotic-resistant infections, a USPTO-granted patent in 2021 for 3D-printable hydrogels licensed from Dartmouth College, and a 2022 provisional patent filing for Therapeutic Polypseudorotaxane Hydrogels targeting central nervous system conditions. The company targets healthcare providers, research institutions, and patients in the neuronal therapeutics and infectious disease sectors, pursuing strategic alliances with universities and scientists in stem cells, tissue engineering, and drug development.
Qrons Announces the Addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board to Beef up its Team, as Part of its New Sepsis Research Program
Qrons Announces Launch of its New Website in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
Qrons Announces the Filing of a Provisional Patent Application in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and Traumatic Brain Injuries